Misoprostol and active management of the third stage of labor

ObjectiveTo compare current practices for the active management of the third stage of labor (AMTSL) with the use of 600 μg of oral misoprostol.MethodsAn operations research study was designed to compare blood loss with current AMTSL practices and misoprostol use.ResultsWomen in the misoprostol group were less likely to bleed 500 ml or more (adjusted odds ratio, 0.30; 95% confidence interval, 0.16–0.56) compared with those in the current practices group. In the current practices group 73% women required interventions because of postpartum hemorrhage, compared with 11% in the misoprostol group.ConclusionIn situations where oxytocin and or ergometrine are not consistently and appropriately used during third stage of labor, misoprostol should be considered for inclusion in the AMTSL protocol.